Beat The Heat: Sleep, Health and Safety in Hot Weather and Heatwaves For Babies and Pregnant Mothers
'As our climate warms, it's imperative that caregivers and health practitioners understand and anticipate the unique challenges heatwaves pose to families'— Eline Holvoet, MD
BRUSSELS, BELGIUM, August 19, 2025 / EINPresswire.com / -- Baby‑Sleep‑Advice.com, the premier source for truly-no-tears, research‑based infant and toddler sleep guidance, today formalized its collaboration with Dr. Eline Holvoet, MD, principal investigator of the WARM (Women's Awareness & Resilience to Maternal Heat‑Health Risks) Study in Belgium as part of the European Commission's HIGH Horizons project.
Through this partnership, rigorous maternal‑child heat‑health research is paired with practical, freely accessible resources to help families navigate hot‑weather challenges.
Downloadable Flyers Backed by WARM Study
– Beat The Heat Tips for Babies: A concise, printable PDF presenting vital preventive measures - such as minimal sleepwear, safe cooling strategies, and hydration reminders - to protect infants and toddlers from heat‑related illness and disrupted sleep.
– Beat The Heat Tips for During Pregnancy: Tailored guidance for expectant mothers on recognizing heat‑stress symptoms, maintaining adequate fluids, and using simple cooling techniques.
Both high‑resolution flyers are available for free download and ideal for online sharing or community distribution. Parents, caregivers, and health professionals can request permissioned, print‑quality versions via the contact details below.
Broad Sleep & Heat‑Safety Guidance
'As our climate warms, it's imperative that caregivers and health practitioners understand and anticipate the unique challenges heatwaves pose to families,' said Dr. Eline Holvoet, MD.
The 'Beat The Heat' collaboration with Heidi Holvoet, PhD of Baby-Sleep-Advice.com also delivers specific strategies to maintain comfortable sleep environments during heatwaves - covering clothing choices, hydration practices, and room‑cooling methods - that parents can effectively apply in every situation.
Community Engagement & Support
Families and caregivers are invited to join Rested!, Baby‑Sleep‑Advice.com's private community platform, to discuss and have their questions answered related to the WARM Study's findings and how to apply these into everyday caregiving practices.
Helping Families Recognize What Matters Most
The guidelines for sleep in hot weather emphasize safety and well‑being over perfection in routines. Caregivers are encouraged to temporarily let go of expectations around sleep duration or 'ideal' sleep setups in favor of simple, achievable adjustments that prioritize the baby or toddler's comfort and health during hot spells. Whether that means a daytime nap outdoors in the shade or using a diaper‑only sleep setup indoors, the message is clear: flexibility helps protect well‑being.
For Homes Without Air Conditioning
For families who lack access to fans or air conditioning, the guide offers practical, low‑tech solutions such as placing a large block of ice in a safe container in the bedroom to cool ambient air, or spending parts of the day in naturally cooler areas of the home. These solutions ensure that the advice is inclusive and accessible to households regardless of income or resources.
An Urgent Call for Awareness
The collaboration comes at a crucial time, as many regions experience increasingly frequent and intense heatwaves. With infants and pregnant women among the most vulnerable to heat stress, Baby‑Sleep‑Advice.com and the WARM Study aim to distribute these resources widely. Caregivers, professionals, and community organizations are encouraged to share the materials and spread awareness because, as they underscore, 'every protection measure counts.'
Heidi Holvoet
Heidi Holvoet | Baby Sleep Advice
+32 485 30 86 36
email us here
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
23 minutes ago
- Medscape
Do Women With Acute ACS Face Unnecessary Bleeding Risk?
A consensus statement from two European cardiology organizations contends antithrombotic treatment for myocardial infarction and angina overlooks sex differences that heighten bleeding risk in women. Compared with men, women treated for acute coronary syndromes (ACS) are at a greater risk for in-hospital bleeding related to invasive cardiac procedures and more long-term outpatient bleeding events, according to the statement from the European Association of Percutaneous Cardiovascular Interventions and the European Society of Cardiology Working Group on Thrombosis. Antithrombotic therapies such as heparin and fondaparinux used in invasive ACS procedures typically have a similar efficacy in women and men, but women have a higher bleeding risk of these agents, said Davide Capodanno, MD, PhD, professor of cardiology at the University of Catania, Catania, Italy, and co-author of the consensus statement. Some ways to reduce bleeding risk in women are to adjust antithrombotic dosing for body weight and kidney function, Capodanno told Medscape Medical News , and to opt for radial access over femoral access for percutaneous coronary intervention (PCI). 'Our paper shows that women still experience delays in diagnosis and treatment, receive excessive antithrombotic doses more often, and remain underrepresented in trials,' Capodanno said. 'All of this creates the need for clear, pragmatic, sex-informed recommendations.' Physiologic Differences Hormonal differences between men and women play an important role in bleeding risk. Estrogen promotes the production of prostacyclin, increases the availability of nitric oxide, and reduces platelet aggregation. These features might protect against the earlier onset of coronary artery disease, but fluctuations in hormonal status due to the menstrual cycle, use of oral contraceptives, menopause, and hormone replacement therapy can also influence thrombotic and bleeding risks. Sex differences in protease-activated receptor signaling pathways, smaller coronary artery sizes, and a cascade of other factors contribute to the greater risk for bleeding associated with ACS treatment (Figure). Although ACS typically affects postmenopausal women, the incidence is increasing in premenopausal women, whose bleeding risk is even more elevated because of lower platelet reactivity due to estrogen receptors on the platelet surface. Data from nearly 4000 women and 10,000 men undergoing PCI showed women younger than 50 years were four times more likely than men of the same age to experience major and minor bleeding events associated with stenting. Wanted: More Sex-Specific Data Women also often experience delays in the diagnosis of ACS and referral for invasive treatments, such as PCI, for their condition. Clinicians still lack strong evidence to help them address sex differences in clotting and response to anticoagulation, Capodanno suggested. Awareness is improving, but there's still work to be done. 'We simply don't have enough sex-powered data to guide all our decisions. Women remain underrepresented in clinical trials, which limits the strength of sex-specific evidence,' Capodanno said. 'We need to push for more equitable research by enrolling and retaining more women in clinical studies and ensuring that results are analyzed and published separately for men and women.' Sunil V. Rao, MD, lead author of the 2025 joint clinical practice guidelines on ACS from the American College of Cardiology and the American Heart Association, agreed. 'There are very few clinical trials of bleeding reduction that have strong female representation,' said Rao, deputy director of the Leon H. Charney Division of Cardiology and director of interventional cardiology at NYU Langone Heart in New York City. One such study, the SAFE-PCI for Women randomized trial Rao led, compared radial access and femoral access in women undergoing stenting. The research showed using radial instead of femoral access for the intervention reduces the risk for bleeding in women. 'We need more trials like this to help guide the clinical community on how to mitigate the risks of antithrombotic therapy in women,' Rao said. Take-Home: Male Isn't Norm How can individual clinicians adjust their practice? 'We recommend actively reducing bleeding risk — for example, using radial access whenever possible, using ultrasound guidance if femoral access is needed, and always avoiding overdosing by adjusting for weight and kidney function,' Capodanno said. Prompt treatment is key to avoid sex-related delays in starting antithrombotic medications. 'Also, be mindful of sex-specific presentations in ACS,' he added. Among these is myocardial infarction with nonobstructive coronary arteries, which includes spontaneous coronary artery dissection, responsible for 25%-35% of myocardial infarctions in women younger than 50 years. According to Rao, European guidelines are generally consistent with North American recommendations with respect to antithrombotic strategies for ACS. 'I don't think we can make strong recommendations to change practice just yet,' he said. 'The message really is to counsel patients, especially female patients, on the benefit-risk balance of antithrombotic therapy, to use evidence-based approaches to reduce bleeding risk — such as radial access — and to refer female patients for clinical trials when possible.' Capodanno reported payment for speaker fees and advisory board participation from Bristol Myers Squibb, Daiichi Sankyo, Novo Nordisk, Sanofi, and Terumo. Rao reported no relevant financial conflicts of interest.
Medscape
23 minutes ago
- Medscape
Early Access to Weight Loss Jabs in NICE Diabetes Plan
People with type 2 diabetes (T2D) in England could be offered earlier access to newer treatments, including weight loss jabs, under draft guidance from the National Institute for Health and Care Excellence (NICE). The guidance, described as the 'biggest shake-up in care for a decade', would see a shift from a one-size-fits-all approach to a focus on personalised treatment to prevent heart failure, heart attacks, and other serious complications. Expanded Use of SGLT-2 Inhibitors The draft guidance recommends expanding access to sodium-glucose co-transporter-2 (SGLT-2) inhibitors, including canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin. Currently prescribed as a second-line option, SGLT-2 inhibitors would be available as a joint first-line treatment alongside metformin. They may also be used as monotherapy in patients intolerant to metformin. SGLT-2 inhibitors are once-daily tablets that selectively block the SGLT-2 cotransporter in the proximal renal tubule, responsible for reabsorbing about 90% of filtered glucose. This lowers the renal glucose threshold, increasing urinary glucose excretion and inducing mild osmotic diuresis. However, a 2024 NICE analysis of nearly 590,000 people with T2D in England found under-prescribing of these drugs, particularly among women, older adults, and Black patients. Only 20% of patients with atherosclerotic cardiovascular disease received SGLT-2 inhibitors, with prescribing rates declining in older age groups. NICE estimates that wider use of SGLT-2 inhibitors could save nearly 22,000 lives once uptake reaches 90%. Earlier Access to GLP-1 Agonists The draft guidance also recommends earlier use of glucagon-like peptide-1 (GLP-1) receptor agonists such as liraglutide or semaglutide. These drugs, previously reserved for later stages of disease, would be considered earlier in treatment for selected groups. NICE further supports wider adoption of digital health tools, including continuous glucose monitoring and community-based digital care. Personalised Treatment Approaches The guidance proposes tailored treatment strategies based on patient characteristics and comorbidities: Adults with cardiovascular disease should receive triple therapy (metformin, an SGLT-2 inhibitor, and a GLP-1 receptor agonist) Those with early-onset T2D (diagnosed before age 40) should receive dual therapy before considering a GLP-1 receptor agonist Patients with obesity or chronic kidney disease should have specific combinations based on their condition and kidney function, respectively. Adults with clinical frailty should start with metformin monotherapy. Professor Jonathan Benger, deputy chief executive and chief medical officer at NICE, said the draft guidance marks a 'significant evolution' in diabetes care. 'The evidence shows that certain medicines can provide important cardiovascular benefits, and by recommending them as part of initial treatment, we could help prevent heart attacks, strokes, and other serious complications before they occur,' he said. Burden of Diabetes in the UK Approximately 4.6 million people in the UK have diabetes, with 90% diagnosed with T2D. Diabetes UK estimates that a further 1.3 million may be undiagnosed. The condition costs the NHS £1 million per hour, with 60% of spending linked to complications. Each week, diabetes contributes to more than 930 strokes, 660 heart attacks, and nearly 2990 cases of heart failure. Douglas Twenefour, head of clinical at Diabetes UK, welcomed the draft guidance. 'The majority of people with T2D are not currently taking the most effective medication for them, putting them at risk of devastating diabetes-related complications,' he said. 'Tailoring treatment based on individual risk could protect thousands against heart attacks and kidney disease.' Waqaar Shah, a GP partner at Chatfield Health Care in London and chair of the NICE guideline committee, said that these recommendations 'could help reduce health inequalities while providing better outcomes for everyone'. Implementation and Safety The draft guidance remains open for public consultation until 2 October. NICE will review feedback before publishing final recommendations. The guidance aims to promote equitable access to recommended therapies, supported by local training initiatives. Healthcare professionals have also stressed the need for safe prescribing of SGLT-2 inhibitors, which carry risks including diabetic ketoacidosis (DKA). Before starting treatment, providers should assess whether patients have previously experienced DKA, have acute illness, or follow very low-carbohydrate or ketogenic diets.
Yahoo
28 minutes ago
- Yahoo
Madrigal wins European MASH approval as Novo rivalry looms
Madrigal Pharmaceuticals' Rezdiffra (resmetirom) has been approved in Europe for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis, making it the first targeted therapy available for patients in the region with this severe form of liver disease. The conditional marketing authorisation by the European Commission (EC) follows an approval recommendation by the European Medicines Agency (EMA)'s Medicinal Products for Human Use (CHMP) in June. US pharma Madrigal expects to launch Rezdiffra in Europe on a country-by-country basis, starting with Germany in Q4 2025, as per a 19 August statement. Stock in US-listed Madrigal closed 2.2% down to $379.55 per share at market close on 19 August, with investors likely downbeat amid a tangential development. Viking's oral glucagon-like peptide-1 receptor agonist (GLP-1RA) drug posted disappointing trial results on the same day; Madrigal recently outlaid $2bn in an oral GLP-1RA licensing deal. The regulatory approval means Madrigal is the only pharmaceutical company with an approved MASH drug in Europe. Rezdiffra was also the first MASH treatment to market in the US – winning US Food and Drug Administration (FDA) approval in March 2024. MASH develops when there is a significant buildup of fat in the liver. Fibrosis, also known as scarring, is associated with MASH, and left untreated, it can lead to more serious damage, including cirrhosis. Madrigal estimates that approximately 370,000 patients have been diagnosed with MASH with moderate to advanced fibrosis in Europe. The disease is a form of non-alcoholic fatty liver disease (NAFLD) that has been billed as one of pharma's highest potential growth areas. Analysis by GlobalData forecasts sales of $25.7bn in 2032 across the seven major markets (the US, France, Germany, Italy, Spain, the UK, and Japan), meaning Madrigal's first-to-market credentials in both the US and Europe could bode well for the drug's growth. GlobalData forecasts a high ceiling for Rezdiffra. The drug is expected to reach blockbuster status by the end of 2026, and, by 2031, Rezdiffra is forecast to generate $4.8bn in global sales. GlobalData is the parent company of Pharmaceutical Technology. Administered as a daily pill, Rezdiffra works by activating a thyroid hormone receptor that reduces liver fat accumulation. While Madrigal was first to reach market in the US for a MASH treatment, it has since lost its crown of boasting the only approved therapy in the indication. Earlier this week, Novo Nordisk's blockbuster drug Wegovy (semaglutide) won FDA approval for the treatment of MASH with moderate to advanced liver fibrosis, providing direct competition to Rezdiffra. Novo Nordisk has also applied for regulatory approval in the EU, setting up a second potential rivalry with Madrigal. However, unlike Wegovy, which exerts its effect through agonism of the GLP-1 receptors, Madrigal's treatment works directly in the liver itself. GlobalData senior analyst Jay Patel says: "This approval allows Madrigal's Rezdiffra to establish an early lead in the EU MASH market. Nevertheless, Novo Nordisk's Wegovy is set to follow closely behind, with an approval expected imminently. "It remains to be seen whether Rezdiffra will be able to carve out a niche once this takes place, given greater patient and physician familiarity with Wegovy, which is already approved for common MASH comorbidities such as obesity and type 2 diabetes mellitus." The EC based its approval on results from the Phase III MAESTRO-NASH trial, in which Rezdiffra achieved both fibrosis reduction and MASH resolution primary endpoints. The pill also reduced liver stiffness, liver fat, liver enzymes, and atherogenic lipids in the MAESTRO-NASH trial, and improved health-related quality of life. Madrigal's CEO Bill Sibold said: 'MASH is the fastest-growing indication for liver transplantation in Europe, but until now, it had no approved treatment. The European labelling for Rezdiffra will set an important precedent for the entire field, with no biopsy required to qualify for treatment with Rezdiffra and a clear focus on a distinct MASH patient population with high unmet need.' Before Madrigal and Novo's approvals, MASH had become a graveyard of failed candidates. Gilead, AstraZeneca, and Intercept all fell short in getting candidates to market, all eventually pivoting pipelines away from the indication. "Madrigal wins European MASH approval as Novo rivalry looms" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
